First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Ryan J. Sullivan(Dana-Farber Cancer Institute), Bob T. Li(Memorial Sloan Kettering Cancer Center), Mario Sznol(Yale Cancer Center), Andrea Wang‐Gillam(Washington University in St. Louis), Keith T. Flaherty(Massachusetts General Hospital), Anna M. Varghese(Memorial Sloan Kettering Cancer Center), Sapna P. Patel(The University of Texas MD Anderson Cancer Center), Gary DeCrescenzo(Phenomenome Discoveries (Canada)), Mary Varterasian(Phenomenome Discoveries (Canada)), Geoffrey I. Shapiro(Brigham and Women's Hospital), Deborah Jean Lee Wong(University of California, Los Angeles), Anna Groover(Phenomenome Discoveries (Canada)), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Saurabh Saha(Phenomenome Discoveries (Canada)), Elizabeth I. Buchbinder(Dana-Farber Cancer Institute), David M. Hyman(Cornell University), Filip Jankú(The University of Texas MD Anderson Cancer Center), Jeffrey A. Sosman(Palmetto Hematology Oncology), Antoni Ribas(University of California, Los Angeles), Richard D. Carvajal(Memorial Sloan Kettering Cancer Center), Vicki L. Keedy(Vanderbilt University Medical Center), Jeffrey R. Infante(Tennessee Oncology), James W. Mier(Hadassah Medical Center), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center), Dean J. Welsch(Phenomenome Discoveries (Canada)), Manish R. Patel
Cited by 418
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k